Paper Details

  1. Home
  2. Paper Details

Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers.

Author: MenheereP P, NautaJ J, Nieuwenhuijzen KrusemanA C, SelsJ P, WolffenbuttelB H

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Miglitol did not have any clinically relevant extraintestinal effects on glucose control in healthy volunteers.
Paper Details　
Original Abstract of the Article :
In this double-blind, cross-over, placebo-controlled, randomized study, possible extraintestinal effects of miglitol, an absorbable alpha-glucosidase inhibitor, were investigated. Sixteen healthy male volunteers underwent two 75 g oral glucose tolerance tests with concomitant administration of migli...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1046/j.1365-2125.1996.44216.x

データ提供：米国国立医学図書館（NLM）

Miglitol: No Extraintestinal Effects on Glucose Control

Miglitol, an alpha-glucosidase inhibitor, is a medication used to manage blood sugar levels in individuals with type 2 diabetes. This study explores the potential extraintestinal effects of miglitol on glucose control in healthy volunteers. Researchers conducted a double-blind, cross-over, placebo-controlled study to assess the impact of miglitol on glucose, insulin, and C-peptide levels, providing valuable insights into the drug's metabolic effects.

Miglitol: Targeted Action on Glucose Control

The study demonstrated that miglitol does not exert clinically relevant extraintestinal effects on glucose control in healthy volunteers. This finding suggests that miglitol's effects are primarily confined to the gastrointestinal tract, supporting its safety profile and targeted action on glucose metabolism.

Understanding Miglitol's Effects: A Guide for Safe and Effective Use

This research provides reassurance regarding the safety and specificity of miglitol's effects on glucose control. It highlights the importance of understanding the targeted action of medications to ensure safe and effective use.

Dr. Camel's Conclusion

Just as a camel can traverse vast distances with minimal water, miglitol seems to work its magic specifically on glucose control without significant impacts on other areas. This study assures us of its targeted action, providing valuable insights into its safety profile.

Date :
  1. Date Completed 1997-02-18
  2. Date Revised 2019-05-12
Further Info :

Pubmed ID

8904624

DOI: Digital Object Identifier

10.1046/j.1365-2125.1996.44216.x

Related Literature

Article Analysis
・Effects of miglitol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.